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Abstract
The Ets transcription factor, ESX, exhibits a unique pattern of epithelial-restricted expression and transactivates genes involved in epithelial
differentiation and cancer. The aim of this study was to determine the underlying genetic basis for epithelial-specific expression of ESX. We have
identified a 30bp ESX enhancer sequence (EES) approximately 3 kb upstream of the proximal promoter. This region displays enhancer activity in
an epithelial-specific manner and deletion of this region abrogates ESX gene transcription. An EES binding protein complex (EBC) was identified
through electrophoretic mobility shift assays whose degree of EES binding correlated well with endogenous ESX levels in epithelial cells and was
regulated by epithelial differentiation. Understanding the regulation of this element will lend insight into mechanisms of epithelial differentiation
and the etiology of breast cancer and may provide novel targets for cancer therapeutic intervention.
© 2005 Elsevier B.V. All rights reserved.
Keywords: Ets; Differentiation; Breast Cancer; ELF3; ESE1

1. Introduction
Ets transcription factors regulate gene expression during
a number of biologic processes including proliferation,
transformation, differentiation, morphogenesis and development. The Ets family comprises more than 40 members,
many of which have been shown to be involved in the
development and homeostasis of cell lineages as well as in
the genesis of human cancer (Dittmer and Nordheim, 1998;
Sharrocks, 2001). Null mutations of various Ets factors

Abbreviations: RA, retinoic acid; Act. D, actinomycin D; TGF-β, transforming growth factor beta; TGF-βRII, type II TGF-beta-receptor; MAPK,
mitogen-activated protein kinase; PI3K, phosphoinositide-3 kinase; EMSA,
electrophoretic mobility shift assay; hFib, human fibroblasts.
⁎ Corresponding author. Lawrence Berkeley National Laboratory, 717 Potter
Street, Berkeley, CA 94710-2722, USA. Tel.: +1 510 486 6815; fax: +1 510 495
2535.
E-mail address: rmneve@lbl.gov (R.M. Neve).
0378-1119/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.gene.2005.10.001

result in embryonic or neonatal lethality indicating a critical
role in early development (Remy and Baltzinger, 2000; Ng
et al., 2002) whereas genetic translocations of Ets genes are
associated with early life cancers and leukemias (Dittmer
and Nordheim, 1998). While there has been extensive
research into the role of Ets factors in haemopoeitic
lineages very little is known about Ets factors in epithelial
lineages.
Recently, a number of independent reports identified a
novel Ets factor, ESX (also termed Elf3, Jen, Ert and Ese1), which is associated with mammary gland development,
carcinogenesis and epithelial differentiation (Andreoli et al.,
1997; Oettgen et al., 1997; Tymms et al., 1997; Neve et
al., 1998; Chang et al., 1999; Brembeck et al., 2000;
Yoshida et al., 2000). ESX is of particular interest as it
is found exclusively expressed in terminally differentiated
epithelial cells in the mammary gland, colon, trachea,
kidney, prostate, uterus, stomach and skin under homeostatic conditions (Andreoli et al., 1997; Oettgen et al.,
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1997; Tymms et al., 1997; Neve et al., 1998). A number
of genes have been identified as transcriptional targets of
ESX, including transforming growth factor beta-type-II receptor (TGF-β RII) (Choi et al., 1998; Kim et al., 2002),
several differentiation-specific markers (Andreoli et al.,
1997; Oettgen et al., 1997; Brembeck et al., 2000;
Yoshida et al., 2000), MIP3-α (Kwon et al., 2003), nitric
oxide synthase (Rudders et al., 2001) and tumour-associated genes (Eckel et al., 2003). ESX is also a putative
mediator of inflammatory shock and host defense (Rudders
et al., 2001) and it is in response to inflammatory stimuli
that ESX expression is induced in non-epithelial cells (Rudders et al., 2001). In breast cancer, ESX expression is
significantly correlated with ErbB2 expression, and is a
downstream transcriptional target of ErbB2 (Neve et al.,
2002).
Here we sought to identify cis-acting elements within the
ESX locus that control the epithelial-specific expression of
ESX. We describe a 30-bp enhancer element approximately 3
kb upstream of the transcriptional start point that directly
controls ESX expression. This ESX enhancer sequence
(EES) is regulated in response to differentiation and appears
to be positively controlled by an EES binding protein complex (EBC).
2. Materials and methods
2.1. Cell culture and transient transfection assays
Sk-Br-3 cells were grown in McCoys5A medium supplemented with 10% fetal calf serum. MCF7 cells were grown
in Dulbecco's modified Eagle's medium (DMEM) 1 g/L
glucose supplemented with 10% fetal calf serum and
0.01mg/ml bovine insulin. MCF10A and MCF12A cells
were grown in a 50:50 mix of DMEM/Hams F12 supplemented with 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.01
mg/ml insulin, 50 ng/ml hydrocortisone and 5% horse
serum. HC11 cells were grown in RPMI medium supplemented with 10% fetal calf serum, 5 μg/ml insulin and 10
ng/ml EGF. Human fibroblasts were maintained in a 50:50
mix of DMEM/Hams F12 supplemented with 5 μg/ml Insulin and 10% fetal calf serum. All cells were grown at 37
°C and 5% CO2.
Transient transfections were carried out using Effectene
(Qiagen) transfection reagent according to manufacturer's
instructions. Briefly, cells were grown in 6-well plates
and transfected at approximately 50% confluency. For
each well 1 μg of the luciferase reporter plasmid and
0.5 μg of LacZ plasmid (internal control) were co-transfected to control for transfection efficiency. After 24
h cells were washed in phosphate-buffered saline (PBS)
and extracted using passive lysis buffer (Promega) and
luciferase assays performed with a luciferase assay system
(Promega) and luminometer. Beta-galactosidase values
were obtained using a chemiluminescent reporter assay
system (Tropix Galactolight Assay) and used to normalize
luciferase values.
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2.2. Immunochemical techniques
For immunoblot analysis, cleared cell lysates were electrophoretically resolved on denaturing sodium doedecyl sulphate
(SDS)-polyacrylamide gels (4–12%), transferred to polyvinylidene difluoride (PVDF, Millipore), and probed with specific
antisera. The primary antibody to ESX was prepared and purified as in Chang et al. (1997).
2.3. Northern analysis
For Northern blotting, total cellular RNA was purified from
cells using RNeasy (Qiagen). RNA (20 ug/sample lane) was
electrophoresed through 1% formaldehyde-agarose gels and
transferred to nylon membranes. Blots were probed with a cterminal single-stranded PCR-amplified DNA fragment
corresponding to the anti-sense strand of the last 400 bp of
the 3′ ESX cDNA sequence. After annealing and a final wash at
65 °C in 0.2 × SSC the membrane was exposed to film and the
autoradiograph developed.
2.4. Reverse-transcriptase PCR
RNA was isolated from cells using the RNeasy kit (Quiagen), and semi-quantitative RT-PCR was performed using the
Superscript One Step RT-PCR system (Invitrogen). Briefly, the
reactions were prepared with 0.5 μg total RNA and primers
for ESX (forward: 5′-GATCATTGAGCTGCTGGAGAAGGA3′, reverse: 5′-GTCCCAGTACTCTTTGCTCAGCTT-3′) that
yield a 317 bp product. The cDNA was generated at 50 °C for
30 min. Subsequent denaturation for 2min at 94 °C was followed by 40 cycles of 94 °C, 30 s; 56 °C, 30 s; 72 °C, 45 s. The
RT-PCR products were separated on a 0.8% agarose gel and
visualised under UV light.
2.5. Cell lysates, nuclear extracts and EMSAs
For preparation of protein lysates, cells were washed in
ice cold PBS containing 1mM phenylmethylsulfonyl fluoride (PMSF) and then with a buffer containing 50mM
HEPES (pH7.5), 150 mM NaCl, 25 mM β-glycerophsphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA, 15
mM pyrophosphate, 2 mM sodium orthovanadate, 10 mM
sodium molybdate, leupeptin (10 μg/ml), aprotinin (10 μg/
ml) and 1 mM PMSF. Cells were extracted in the same
buffer containing 1% Nonidet-P40. Lysates were then clarified by centrifugation and frozen at − 80 °C. Protein concentrations were determined using the Bio-Rad protein
assay kit.
Nuclear extracts were prepared using the method of Dignam
et al. (1983). Electrophoretic mobility shift assays (EMSAs)
were performed using 5 μg of nuclear extract and 3 × 104 cpm
of end-labelled double stranded oligonucleotides (EEC sense;
5′-GAAGCCGGTTCTCCCACATTCCTGG-GTGAG-3′, antisense; 5′-CTCACCCAGGAATGTGGGAGAACCGGCTTC3′). Binding reactions were performed at room temperature
for 15 min. Reactions were carried out in 20 μl of DNA
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Table 1
Oligonucleotide sequences used for cloning of various ESX reporter constructs
Construct H/
M

5′/
3′

Oligonucleotide sequence

− 347
Luc
− 2900
Luc
− 351
Luc
HrII

H

HrIII

H

−2218
Luc
− 2002
Luc
− 1976
Luc
− 1946
Luc
− 1906
Luc

H

5′
3′
5′
3′
5′
3′
5′
3′
5′
3′
5′
3′
5′
3′
5′
3′
5′
3′
5′
3′

CCGCCTCGAGTCAGCCCTGGCCAGGCCCCCAGG
CCGCAAGCTTTAGAGCAAAGCAGGAGCTCCT
CCGCCTCGAGGGATCCTTCCAAGGCACTGACC
CCGCAAGCTTTAGAGCAAAGCAGGAGCTCCT
CCGGCTAGCCCATCTCTGGCCTGGCCCCTGGG
CCGAAGCTTAGAGGATGAGGTTGGTGAGGGGAC
CCGGCTAGCGAATATGTTGAAAAGTGCTTGG
CCGGCTAGCCACTCTGTTGGCAAGGTCTTC
CCGGCTAGCCCCCATCCCCATGCCTCCAAG
CCGGCTAGCCAGGAGAGCCTGGGGCTCAGT
CCGGCTAGCCCCCATCCCCATGCCTCCAAG
GAGTGCAGTGGCGTGATATCTG
CCGGCTAGCGGAGCACGTGAGCAGCCCTGGGG
GAGTGCAGTGGCGTGATATCTG
CCGGCTAGCGAAGCCGGTTCTCCCACATTCC
GAGTGCAGTGGCGTGATATCTG
CCGGCTAGCGGACTGGGTGGAGGGTGTGCC
GAGTGCAGTGGCGTGATATCTG
CCGGCTAGCGAGGCCCCCTGAAGGGCTGGGG
GAGTGCAGTGGCGTGATATCTG

M
M
H

H
H
H
H

binding buffer (20 mM HEPES (pH 7.6), 100 mM KCl, 1
mM DTT, 0.1% Triton X-100, 2 mM MgCl2 and 20%
glycerol), 3 μg of poly(dA-dT) was added to each reaction

as nonspecific DNA. For competition assays, 100-fold excess
cold oligonucleotides were added to the reaction mix before
adding nuclear extracts. The protein–DNA complexes were
resolved by gel electrophoresis on 4% polyacrylamide gels.
After electrophoresis, the gels were dried and visualized by
autoradiography.
2.6. DNA constructs and oligonucleotides
All luciferase constructs were constructed using the pGL3
vector system and were sequence verified before use. Primers
used to PCR out DNA regions are in Table 1.
The mouse − 2900 Luc and − 347 Luc constructs were
cloned by PCR amplification of the relevant regions and cloned
I/HindIII into pGL3-basic. The full length human − 2872 region
was excised from a previous pGL2-backbone construct (described in Neve et al., 2002) using a NheI–HindIII digest and
shuttled into pGL3-Basic cut NheI–HindIII to create − 2872
Luc. To generate truncations of − 2872 Luc the truncated upstream regions were amplified using PCR. All constructs were
amplified to include a 3′ XbaI site present at − 1792 in the
original construct. The PCR fragment and an XbaI–HindIII
fragment contain the proximal promoter and the upstream sequence to − 1792 were simultaneously cloned into pGL3-Basic
cut NheI–HindIII. HrII and HrIII were generated using the

Fig. 1. (A) Genomic organization of the mouse and human ESX loci (to scale, Accession AY456682 and AF110184 respectively). Sequencing of the human and
mouse genomic sequence encompassing the ESX locus shows conservation of the exons (labeled 1–9). Further comparison reveals three conserved regions of DNA
upstream of the transcriptional start site, termed homology region-I, -II and -III (HrI, II and III). HrI encompasses the previously reported proximal promoter, HrII and
HrIII represent newly identified regions of homology upstream of HrI. (B) Luciferase constructs containing either HrI (Mouse: − 347 Luc; Human: − 351 Luc) alone
or all three homology regions (Mouse: − 2900 Luc; Human: −2872 Luc) for both mouse and human were transiently transfected into Sk-Br-3 cells and the basal
luciferase activity measured after 24 h as described in Materials and methods. Each experiment was performed in triplicate and results are representative of at least
three independent experiments.
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primers in Table 1. A NheI site was generated at either end to
clone into − 351 Luc or pGL3-Promoter, both cut NheI. Directionality was determined by PCR analysis. All constructs containing the HrI (proximal promoter) extend to + 519 (see Neve
et al., 2002).
Cloning of small regions of the putative enhancer elements
(− 2036–2002;− 2002–1976;− 1976–1946) was accomplished
through annealing of complementary, phosphorylated oligonucleotides with KpnI/NheI overhangs which were cloned into
− 351 Luc or pGL3-Promoter each cut KpnI/NheI.
3. Results
3.1. Evidence for a cis-acting enhancer element upstream of
the ESX gene
Previously we published the sequence of a 350 bp ESX gene
proximal promoter (Neve et al., 1998). Both the mouse and
human promoters showed extensive homology (77% over 350
bp) and were serum and mitogen responsive. Alignment of 3 kb
of genomic sequence extending upstream of the proximal promoters of both the mouse and human ESX gene revealed two
additional regions of significant homology (termed homology
regions II (HrII) and III (HrIII)) in addition to the proximal
promoter (termed homology region I (HrI))(Fig. 1A). HrII and
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HrIII exhibit 83% homology over 383 bp and 63% homology
over 293 bp, respectively. Mouse and human luciferase reporter
constructs containing upstream sequence encompassing all
three Hr regions (− 2900 Luc and − 2872 Luc, respectively)
were found to have significantly higher luciferase activity in
comparison to the constructs encoding the HrI (− 347 Luc and
− 351 Luc, respectively) alone (Fig. 1B) in the human breast
cancer cell line, Sk-Br-3. This suggests the presence of one or
more enhancer elements upstream of HrI in both the mouse and
human genomes.
The basal activity of the human − 2872Luc reporter correlates well with endogenous ESX expression levels in a panel of
cell lines (Neve et al., 2002). Comparison of the human − 351
Luc with − 2872 Luc activity in five untreated epithelial breast
cancer cell lines with varying ESX expression levels revealed
only the longer construct exhibited activity that varied in conjunction with the basal ESX level of each cell line (from barely
detectable levels in MCF10a cells to highly expressed levels in
Sk-Br-3 cells). This implies the upstream sequence of the ESX
promoter likely contains a cis-acting enhancer region controlling cell-to-cell variation in endogenous ESX expression (Fig.
2). Since ESX expression is restricted to epithelial cells
(Andreoli et al., 1997; Chang et al., 1997; Oettgen et al.,
1997; Tymms et al., 1997), it is likely that this cis-acting
enhancer region contains an epithelial-specific response
element.
3.2. ESX expression is regulated by an epithelial-specific
enhancer element

Fig. 2. The upstream enhancer shows epithelial specificity and reflects endogenous ESX protein levels. Transient luciferase assays were used to measure the
transcriptional activity of both mouse and human constructs encompassing
either the Hr1 (proximal promoter) region or all three homology regions in
four human breast epithelial cell lines (Sk-Br-3, MCF-7, MCF10A and
MCF12A) and one human fibroblast cell line (hFib). Luciferase assays were
performed as described in Materials and methods. Each experiment was performed in triplicate and results are representative of at least three independent
experiments. ESX protein levels were determined for each cell line by western
analysis of nuclear extracts (lower panel) as described in Materials and
methods.

To determine whether either HrII or HrIII of the human gene
contained the putative enhancer element, each region was independently cloned upstream of the ESX proximal promoter
driving luciferase expression (− 351 Luc). HrII had no effect on
− 351 Luc transcriptional activity, while HrIII enhanced the
proximal promoter activity to levels equivalent to the entire
upstream sequence, regardless of its orientation (Fig. 3A). HrIII
also significantly enhanced the activity of a heterologous SV40
promoter when introduced into Sk-Br-3 cells but not upon
transfection into human fibroblasts (Fig. 3B). Taken together,
these results suggest that HrIII alone contains an epithelialspecific enhancer element. To determine the minimal element
required for this full enhancer activity, we compared the luciferase activity of sequentially truncated promoter constructs
(Fig. 3C). Initial experiments indicated that the enhancer lays
between − 2036 bp and − 1819 bp within HrIII (not shown).
Further deletions of the 5′ sequence identified a 30 bp ESX
enhancer sequence (EES) (− 1976 bp to − 1946 bp) within HrIII
which is required for full activity of HrIII (Fig. 3C, top panel).
All constructs transfected into human fibroblasts exhibited promoter activity equivalent to the proximal promoter (− 341 Luc),
confirming the lack of significant EES enhancer activity in nonepithelial cells (Fig. 3C, lower panel).
Sequence comparison of the human and mouse HrIII regions
revealed several clusters of conserved putative transcription
factor-binding sites, several Ikaros isoforms localized to the
EES are depicted (Fig. 4A) (Quandt et al., 1995). Consistent
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Fig. 3. HrIII encodes a putative epithelial-enhancer element. Transient transfection of (A) luciferase constructs containing either HrII or HrIII (in positive (+) or
negative (−) orientation) cloned upstream of HrI (proximal promoter) into Sk-BR-3 cells, (B) HrIII (in positive (+) or negative (−) orientation) cloned upstream of the
SV40 promoter (pGL3-promoter vector) into Sk-Br-3 cells or human fibroblasts, (C) serial deletions of the upstream sequence of the − 2872 Luc promoter into Sk-Br3 cells (upper panel) or human fibroblasts (lower panel) were performed as in Materials and methods. Each experiment was performed in triplicate and results are
representative of at least three independent experiments.

with the deletion constructs, the EES (− 1976bp to − 1946bp) is
sufficient for full enhancer activity when placed upstream of the
− 341 Luc promoter construct, independent of orientation (Fig.
4B). Similarly, when a single copy of the EES was placed
upstream of the heterologous SV40 promoter a ten-fold enhancement of basal promoter activity is observed (Fig. 4C).
Three tandem copies of the EES sequentially arranged upstream of the SV40 promoter increases basal promoter activity
more than 60-fold (Fig. 4C). In keeping with the putative
epithelial specificity of the EES, none of the HrIII constructs
affect promoter activity when introduced into human fibroblasts (Fig. 4C).
3.3. An EES binding complex (EBC) controls ESX enhancer
activity
EMSA assays, using radiolabelled oligonucleotides
corresponding to the EES sequence, revealed two EES-binding
protein complexes. While both protein–DNA complexes were
specifically competed by excess, unlabelled EES oligonucleotide (100 × EES), the slower-migrating complex was completely
competed away in contrast to minimal competition of the faster
migrating (non-specific) complex (Fig 4D, right panel, lane 2).
This indicates a direct relationship between EES-binding EBC
activity, the magnitude of EES trans-activation potential, and

endogenous ESX protein expression among various cell lines.
The EBC EMSA data are consistent with the promoter–reporter
studies and argue that EES constitutes the core enhancer element within the HrIII and likely determines the relative level of
ESX transcription in any given epithelial cell.
3.4. EBC formation is dependent on epithelial differentiation
signals
Since ESX expression is restricted to epithelial tissues and is
involved in epithelial differentiation (Oettgen et al., 1997;
Brembeck et al., 2000; Yoshida et al., 2000; Kim et al., 2002;
Ng et al., 2002) we tested whether epithelial differentiation is
associated with EBC binding to the EES, as detected by EMSA.
We have shown ESX is up-regulated in HC11 cells during
lactogenic competency in the presence of growth factors
(Neve et al., 1998). Using this cell system, we observe that
the EBC–EES complex was induced upon reaching lactogenic
competency (Fig. 5, lanes 2–4). Since our ESX c-terminalspecific antisera does not cross-react with murine ESX, we
were unable to determine ESX protein levels in these mouse
cells; however, RT-PCR analysis showed an increase in ESX
mRNA levels, consistent with the EMSA result (Fig. 5A). To
test how the EBC activity is affected by differentiation signals,
the breast cancer epithelial cell line, MCF-7, was used a model
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Fig. 4. A conserved 30 bp epithelial enhancer element controlling ESX expression. (A) Sequence comparison of HrIII between mouse and human. Alignment of
mouse and human HrIII regions, overall homology with the EES enhancer sequence indicated in bold. Shaded regions indicate perfect homology between the two
sequences. Putative transcription factor binding sites are indicated above the sequence alignment. (B) Transient transfections of the EES cloned upstream of the HrI
(proximal promoter) (− 1976–1947/−351 Luc) in Sk-Br-3 cells compared to − 351 Luc (HrI, the proximal promoter) and −2872 Luc (containing HrI, HrII and HrIII).
(C) Transient transfection of the EES and three tandem copies of the EES placed upstream of the SV40 promoter (pGL3 Promoter) in Sk-Br-3 cells and human
fibroblasts. Transient transfections are described in the Materials and methods and each experiment was performed in triplicate and results are representative of at least
three independent experiments. (D) Electromobility shift assays (EMSA) showing nuclear factors binding the EES. Nuclear extracts from four epithelial cell lines and
one human fibroblast cell line, with differing levels of ESX protein were analysed for DNA–protein complex formation. Results are reflective of several independent
experiments. * = unbound probe; filled arrow = specific band shift; open arrow = non-specific band.

system, since it undergoes differentiation in response to retinoic
acid (RA) (Wang et al., 2000). We found that RA treatment
induced endogenous ESX mRNA and protein levels and increased EES–protein complex within 1 h (Fig 5A, lanes 5–6).
The transcriptional up-regulation of ESX was dependent on denovo RNA synthesis, since treatment of MCF-7 cells with RA
in the presence of actinomycin D prevented an increase in ESX
mRNA levels and ESX protein levels. These results confirm
that binding of EBC to EES appears responsive to epithelial
differentiation signals and may mediate the observed up-regulation of ESX expression that occurs during mammary gland
development and tumorigenesis.
4. Discussion
Epithelial cells play a critical role in the development and
homeostasis of many organs. The same mechanisms controlling
normal epithelial processes are often found perturbed in human
disease such as cancer. However, there is very little information
regarding the control of genes, especially transcription factors,
regulating epithelial differentiation and maintenance. ESX is
clearly involved in the development, differentiation and carci-

nogenesis of epithelial organs including the mammary gland,
however, ESX gene targets and mechanisms of action remain
elusive. Here we report the cis-acting regulatory elements that
control the expression of human ESX.
We previously isolated and sequenced the mouse and human
ESX loci and reported on the transcriptional activity of the ESX
proximal promoter (Neve et al., 1998). The proximal promoter
element and genomic organization of ESX was subsequently
described (Oettgen et al., 1999). Comparison of the human and
mouse upstream genomic sequences has revealed two additional regions of high homology, and detailed analysis of these
regions now reveals an upstream enhancer region bearing a
30 base pair minimal enhancer element. This newly identified
upstream enhancer element described here and termed EES,
exhibits epithelial-specific activity when transfected into a
panel of epithelial and non-epithelial cell lines. This activity
correlates with endogenous levels of ESX in these cells. In
contrast, the proximal promoter element shows similar basal
activity in all cell lines tested. These observations suggest that
endogenous transcription factors capable of binding to the EES
during unstressed conditions are restricted to epithelial cells and
positively control ESX expression. In all experiments this
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Fig. 5. ESX transcriptional activation and epithelial differentiation. (A) The response of ESX transcription to differentiation signals in two epithelial cell lines was
tested. ESX mRNA (measured by RT-PCR), protein levels and EES–EBC binding (measured by EMSA) were observed in control and lactogenic competent HC11
cells, and MCF-7 cells treated with the differentiation-inducing factor, retinoic acid (RA). ESX protein levels can not be detected in HC11 cells as this antibody does
not cross-react with mouse ESX. Results are reflective of several independent experiments. * = unbound probe; filled arrow = specific band shift; open arrow = nonspecific band. (B) To test whether the increase of ESX mRNA and protein levels in response to RA requires de-novo RNA synthesis, MCF-7 cells were treated with
actinomycin D (Act. D) prior to administration of RA. ESX mRNA was detected by Northern blotting (top panel) versus total RNA loading (middle panel) and ESX
protein levels were determined by Western blotting (lower panel). All protocols were performed as described in Materials and methods and are illustrative of several
independent experiments. G = growing; 3D = cells at 3 days confluent; 4D = cells at 4 days confluent.

complex associated with the EES and correlated well with
endogenous ESX expression levels in control cells and in differentiating mouse and human epithelial cells.
The EES element is distinct from one identified by Park et
al. in the ESX proximal promoter region in human gastric
cancers (Park et al., 2001). We found no significant enhancer
binding activity using their DNA binding motif to probe our
panel of breast cancer cell lines (not shown). Recently a mouse
enhancer element was identified (Hou et al., 2004) which is
distinct from the EES. We have found that the mouse enhancer,
which is not present in the human ESX gene, is not functional in
Sk-Br-3 cells; whereas the human ESX enhancer exhibits weak,
but significant, activity in mouse F9 differentiated cells (Rizzino, unpublished data). Overall this points to a complex regulation of ESX that is species-dependent and organ-dependent
within a species.
One hallmark of cancer is a loss of cell differentiation
(Tenen, 2003). ESX plays roles in epithelial differentiation
including that of primary human mammary epithelial cells in

vitro and during in vivo normal mammary gland development
and breast tumorigenesis (Neve et al., 1998, 2002). Our data
suggests that increased ESX expression in breast epithelial cells
decreases cellular proliferation (Neve, unpublished data), which
appears contrary to the function of a cancer-related gene, but is
in keeping with its regulatory role during mammary gland
development. Indeed, reports indicate potential transforming
and apoptotic roles for ESX under specific biological conditions
(Prescott et al., 2004; Schedin et al., 2004). We have previously
shown that transcriptional up-regulation of ESX is downstream
of ErbB receptor activation, primarily mediated by PI3K/PKB
rather than MAPK signaling (Neve et al., 2002); and thus it is
possible that oncogene-associated up-regulation of ESX is necessary to confer cancer-defining cell behavior such as invasiveness and metastatic potential rather than proliferation. Of note
in this regard, TGF-βRII is a transcriptional target of ESX (Choi
et al., 1998; Kim et al., 2002), and co-activation of TGF-β
signaling in conjunction with ErbB2/neu activation has recently
been shown to confer an anti-mitogenic but pro-metastatic
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phenotype (Muraoka et al., 2003; Siegel et al., 2003). By
identifying a critical genetic regulatory element that controls
ESX expression in an epithelial-and tissue-specific manner we
have uncovered a key mechanism potentially common to both
normal epithelial development and carcinogenesis; as such,
future identification of the components of EBC may yield
new breast cancer therapeutic targets.
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